Kristi J. Smock
No Rating Available
(Learn About Our Rating System)

Kristi J. Smock, MD

Languages spoken: English

Dr. Smock is a Professor in the Department of Pathology at the University of Utah. She completed her residency and fellowship training at the University of Utah and is board certified in Anatomic and Clinical Pathology and Hematopathology. She is Vice President and Chief Medical Director for the ARUP Laboratories Institute of Clinical and Experimental Pathology (R&D), leading research and development efforts across traditional laboratory medicine, genetics, and oncology and chairing the ARUP R&D Executive Committee.

Dr. Smock is excited to be a 2025-2026 Hedwig van Amerigen Executive Leadership in Academic Medicine (ELAM) Fellow. The ELAM fellowship is dedicated to developing the professional and personal skills required to lead and manage in today’s complex health care environment. More than 1600 ELAM alumni hold leadership positions in institutions around the world.

Dr. Smock’s primary clinical responsibilities are in hemostasis/thrombosis laboratory medicine, and she is a Medical Director of the Hemostasis/Thrombosis Laboratory at ARUP, where she enjoys being involved in all aspects of the laboratory and providing clinical consultation on difficult coagulation cases. She has additional clinical service responsibilities in hematopathology, where she signs out peripheral smears, bone marrow cases and hematology tests.

Dr. Smock enjoys the educational aspects of academic practice and previously served as the Pathology Residency Program Director at the University of Utah. She has chaired the Clinical Competency Committees for both the residency program and hematopathology fellowship. She received the Department's Outstanding Teaching Award in Clinical Pathology in 2010, 2013, and 2017. She serves on the University of Utah Alpha Omega Alpha medical honor society (AOA) Faculty Board of Directors with an emphasis on resident, fellow, and faculty engagement. In 2018, she received the William Roberts Award for Clinical Excellence in Laboratory Medicine, and in 2022, she received the Joseph A. Knight Award for Excellence in Education, from the University of Utah Department of Pathology. In 2016, Dr. Smock was named as an American Society for Clinical Pathology 40 Under Forty honoree, recognizing her as a leader in Pathology and Laboratory Medicine.

Dr. Smock is an active member of several professional organizations and is current President of the North American Specialized Coagulation Laboratory Association (NASCOLA). She is also current Chair of the College of American Pathologists Hemostasis/Thrombosis Committee and Treasurer of Thrombosis and Hemostasis Societies of North America (THSNA). She was a Summit Co-Chair for the Thrombosis and Hemostasis Societies of North America (THSNA) summits in 2022 and 2024 and a Meeting Co-Chair for the 2023 International Society for Laboratory Hematology (ISLH) annual meeting. She previously represented the Huntsman Cancer Institute for several years on the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines Panel for Cancer-Associated Venous Thromboembolic Disease.

Dr. Smock serves on the Editorial Boards for Research and Practice in Thrombosis and Haemostasis, Seminars in Thrombosis and Haemostasis, and International Journal of Laboratory Hematology, and reviews manuscripts for many other scientific journals. She has served as a Guest Editor for Seminars in Thrombosis and Hemostasis for 5 completed or in progress themed issues related to novel analyzers and diagnostic tests in hemostasis and thrombosis. She has many clinical research interests in coagulation medicine, and her work includes over 100 journal articles, book chapters, abstracts, and other publications in the fields of hemostasis/thrombosis and hematopathology.

Specialties

  • Pathology, Clinical
  • Hematopathology
  • Pathology, Anatomical

Board Certification

American Board of Pathology (Anatomic & Clinical)
American Board of Pathology (Sub: Hematology)

Dr. Smock is a Professor in the Department of Pathology at the University of Utah. She completed her residency and fellowship training at the University of Utah and is board certified in Anatomic and Clinical Pathology and Hematopathology. She is Vice President and Chief Medical Director for the ARUP Laboratories Institute of Clinical and Experimental Pathology (R&D), leading research and development efforts across traditional laboratory medicine, genetics, and oncology and chairing the ARUP R&D Executive Committee.

Dr. Smock is excited to be a 2025-2026 Hedwig van Amerigen Executive Leadership in Academic Medicine (ELAM) Fellow. The ELAM fellowship is dedicated to developing the professional and personal skills required to lead and manage in today’s complex health care environment. More than 1600 ELAM alumni hold leadership positions in institutions around the world.

Dr. Smock’s primary clinical responsibilities are in hemostasis/thrombosis laboratory medicine, and she is a Medical Director of the Hemostasis/Thrombosis Laboratory at ARUP, where she enjoys being involved in all aspects of the laboratory and providing clinical consultation on difficult coagulation cases. She has additional clinical service responsibilities in hematopathology, where she signs out peripheral smears, bone marrow cases and hematology tests.

Dr. Smock enjoys the educational aspects of academic practice and previously served as the Pathology Residency Program Director at the University of Utah. She has chaired the Clinical Competency Committees for both the residency program and hematopathology fellowship. She received the Department's Outstanding Teaching Award in Clinical Pathology in 2010, 2013, and 2017. She serves on the University of Utah Alpha Omega Alpha medical honor society (AOA) Faculty Board of Directors with an emphasis on resident, fellow, and faculty engagement. In 2018, she received the William Roberts Award for Clinical Excellence in Laboratory Medicine, and in 2022, she received the Joseph A. Knight Award for Excellence in Education, from the University of Utah Department of Pathology. In 2016, Dr. Smock was named as an American Society for Clinical Pathology 40 Under Forty honoree, recognizing her as a leader in Pathology and Laboratory Medicine.

Dr. Smock is an active member of several professional organizations and is current President of the North American Specialized Coagulation Laboratory Association (NASCOLA). She is also current Chair of the College of American Pathologists Hemostasis/Thrombosis Committee and Treasurer of Thrombosis and Hemostasis Societies of North America (THSNA). She was a Summit Co-Chair for the Thrombosis and Hemostasis Societies of North America (THSNA) summits in 2022 and 2024 and a Meeting Co-Chair for the 2023 International Society for Laboratory Hematology (ISLH) annual meeting. She previously represented the Huntsman Cancer Institute for several years on the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines Panel for Cancer-Associated Venous Thromboembolic Disease.

Dr. Smock serves on the Editorial Boards for Research and Practice in Thrombosis and Haemostasis, Seminars in Thrombosis and Haemostasis, and International Journal of Laboratory Hematology, and reviews manuscripts for many other scientific journals. She has served as a Guest Editor for Seminars in Thrombosis and Hemostasis for 5 completed or in progress themed issues related to novel analyzers and diagnostic tests in hemostasis and thrombosis. She has many clinical research interests in coagulation medicine, and her work includes over 100 journal articles, book chapters, abstracts, and other publications in the fields of hemostasis/thrombosis and hematopathology.

Board Certification and Academic Information

Academic Departments Pathology -Professor (Clinical)
Board Certification
American Board of Pathology (Anatomic & Clinical)
American Board of Pathology (Sub: Hematology)

Education history

Undergraduate Biology - Utah State University B.S.
Professional Medical Medicine - University of Utah M.D.
Residency Pathology - University of Utah School of Medicine Resident
Fellowship Hematopathology - University of Utah School of Medicine Fellow

Selected Publications

Journal Article

  1. Heikal NM, Murphy KK, Crist RA, Wilson AR, Rodgers GM, Smock KJ (2013). Elevated factor IX activity is associated with an increased odds ratio for both arterial and venous thrombotic events. Am J Clin Pathol, 140(5), 680-5.
  2. Zantek ND, Hayward CP, Simcox TG, Smock KJ, Hsu P, Van Cott EM (2016). An Assessment of the State of Current Practice in Coagulation Laboratories. Am J Clin Pathol, 146(3), 378-83.
  3. Rudolf J, Jackson BR, Wilson AR, Smock KJ, Schmidt RL (2017). Organizational Benchmarks for Test Utilization Performance: An Example Based on Positivity Rates for Genetic Tests. Am J Clin Pathol, 147(4), 382-389.
  4. Smock KJ, Rodgers GM (2009). Laboratory identification of lupus anticoagulants. Am J Hematol, 84(7), 440-2.
  5. Penmetsa GK, Rodgers GM, Smock KJ (2010). Avoiding errors in the laboratory evaluation of potent lupus anticoagulants. Am J Hematol, 85(4), 272-4.
  6. Van Cott EM, Smock KJ, Chen D, Hsu P, Zantek ND, Meijer (2016). Testing for dabigatran and rivaroxaban by clinical laboratories. American journal of hematology, 91(11), E464-E467.
  7. Smock KJ, Rodgers G (2010). Laboratory evaluation of aspirin responsiveness. American journal of hematology, 85(5), 358-60.
  8. Smock KJ, Saunders PJ, Rodgers GM, Johari (2011). Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods. American journal of hematology, 86(12), 1032-34.
  9. Heikal NM, Smock K (2013). Laboratory testing for platelet antibodies. American journal of hematology, 88(9), 818-21.
  10. Gangaraju R, Rets A, Smock KJ, Heikal N (2017). Rare complication of treated immune thrombocytopenia. American journal of hematology, 92(11), 1262-1266.
  11. Herron MD, Vanderhooft SL, Smock K, Zhou H, Leachman SA, Coffin (2004). Proliferative nodules in congenital melanocytic nevi: a clinicopathologic and immunohistochemical analysis. The American journal of surgical pathology, 28(8), 1017-25.
  12. Smock KJ, Perkins SL, Bahler D (2007). Quantitation of plasma cells in bone marrow aspirates by flow cytometric analysis compared with morphologic assessment. Archives of pathology & laboratory medicine, 131(6), 951-5.
  13. Sangle NA, Smock K (2011). Antiphospholipid antibody syndrome. Archives of pathology & laboratory medicine, 135(9), 1092-6.
  14. Schmidt RL, Chute DJ, Colbert-Getz JM, Firpo-Betancourt A, James DS, Karp KJ, Miller DC, Milner DA, Smock KJ, Sutton AT, Walker BS, White KL, Wilson AR, Wojcik EM, Yared MA, Factor R (2017). Statistical Literacy Among Academic Pathologists: A Survey Study to Gauge Knowledge of Frequently Used Statistical Tests Among Trainees and Faculty. Archives of pathology & laboratory medicine, 141(2), 279-287.
  15. Moyer AM, McMillin GA, Long TA, Gandhi MJ, Mao R, Smock KJ, Halley JG, Weck K (2020). Genotype and Phenotype Concordance for Pharmacogenetic Tests Through Proficiency Survey Testing. Archives of pathology & laboratory medicine, 144(9), 1057-1066.
  16. Chandler WL, Brown AF, Chen D, Moser K, Olson JD, Pham HP, Smock KJ, Volod O, Higgins R (2019). External Quality Assurance of Platelet Function Assays: Results of the College of American Pathologists Proficiency Testing Program. Archives of pathology & laboratory medicine, 143(4), 472-482.
  17. Volod O, Brown AF, Chandler WL, Goodwin AJ, Harris NS, Higgins RA, Ison JA, Moser KA, Olson JD, Pham HP, Ravindran A, Rollins-Raval M, Salazar E, Unold D, Smock KJ, VanSandt A, Wool G, Long T, Chen (2022). Interlaboratory performance in measurement of dabigtran and rivaroxaban: Results of the College of American Pathologists external quality assessment program. Archives of pathology & laboratory medicine, 146(2), 145-153.
  18. Smock KJ, Crist RA, Hansen SJ, Rodgers GM, Lehman C (2010). Discard tubes are not necessary when drawing samples for specialized coagulation testing. Blood coagulation & fibrinolysis, 21(3), 279-82.
  19. Staddon JH, Smock KJ, Schiffman JD, Fluchel MN, Engel ME, Weyrich AS, Campbell R (2015). Pegasparaginase treatment alters thrombin generation by modulating the protein C and S system in acute lymphoblastic leukaemia/lymphoma. Blood coagulation & fibrinolysis, 26(7), 840-3.
  20. Desai DS, Lyon E, Rodgers GM, Jama MA, Wallentine SL, Smock K (2015). Elderly female with a personal and family history of a bleeding disorder. Clinical chemistry, 61(7), 909-12.
  21. Khan J, Schmidt RL, Spittal MJ, Goldstein Z, Smock KJ, Greene D (2019). Venous Thrombotic Risk in Transgender Women Undergoing Estrogen Therapy: A Systematic Review and Metaanalysis. Clinical chemistry, 65(1), 57-66.
  22. Hsu P, Zantek ND, Meijer P, Hayward CP, Brody J, Zhang X, Smock KJ, Van Cott E (2014). Factor XIII Assays and associated problems for laboratory diagnosis of factor XIII deficiency: an analysis of International Proficiency testing results. Seminars in thrombosis and hemostasis, 40(2), 232-8.
  23. Smock KJ, Ledford-Kraemer MR, Meijer P, Hsu P, Van Cott E (2014). Proficiency testing results for heparin-induced thrombocytopenia in north america. Seminars in thrombosis and hemostasis, 40(2), 254-60.
  24. Smock KJ, Plumhoff EA, Meijer P, Hsu P, Zantek ND, Heikal NM, Van Cott E (2016). Protein S testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American Specialized Coagulation Laboratories. Thrombosis and haemostasis, 116(1), 50-7.
  25. Shirts BH, Rodgers GM, Smock K (2012). Prothrombin time, activated partial thromboplastin time and dilute Russell's Viper Venom times are not shorter in patients with the prothrombin G20210A mutation, and dilute Russell's Viper Venom time may be longer. Thrombosis research, 130(3), e134-8.
  26. Smock KJ, Yaish HM, Cairo MS, Lones MA, Willmore-Payne C, Perkins S (2007). Mantle cell lymphoma presenting with unusual morphology in an adolescent female: a case report and review of the literature. Pediatric and developmental pathology, 10(5), 403-8.
  27. Mathew Thomas V, Gilreath JA, Newton S, Smock KJ, Lim M (2021). Daratumumab as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy. Haemophilia, 27(4), e563-e566.
  28. Carter-Febres M, Smock KJ, Ware AL, Afify (2021). Improvement of bleeding manifestations of acquired von Willebrand syndrome after balloon aortic valvuloplasty in a child with aortic stenosis. Progress in pediatric cardiology, 60, 101334.
  29. Sangle NA, Agarwal AM, Smock KJ, Leavitt MO, Warnke R, Bahler D, Perkins S (2011). Diffuse large B-cell lymphoma with aberrant expression of the T-cell antigens CD2 and CD7. Applied immunohistochemistry & molecular morphology, 19(6), 579-83.
  30. Crist RA, Gibbs K, Rodgers GM, Smock K (2009). Effects of EDTA on routine and specialized coagulation testing and an easy method to distinguish EDTA-treated from citrated plasma samples. Laboratory hematology, 15(4), 45-8.
  31. Sangle NA, Rodgers GM, Smock K (2011). Prevalence of heparin in samples submitted for lupus anticoagulant testing. Laboratory hematology, 17(1), 6-11.
  32. Liederman Z, Van Cott EM, Smock K, Meijer P, Selby (2019). Heparin-induced thrombocytopenia: An international assessment of the quality of laboratory testing. Journal of thrombosis and haemostasis, 17(12), 2123-2130.
  33. Raetz EA, Perkins SL, Bhojwani D, Smock K, Philip M, Carroll WL, Min D (2006). Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatric blood & cancer, 47(2), 130-40.
  34. Smock KJ, Nelson M, Tripp SR, Sanger WG, Abromowitch M, Cairo MS, Perkins SL, Children's Oncology Group (2008). Characterization of childhood precursor T-lymphoblastic lymphoma by immunophenotyping and fluorescent in situ hybridization: a report from the Children's Oncology Group. Pediatric blood & cancer, 51(4), 489-94.
  35. Tantravahi SK, Williams LB, Digre KB, Creel DJ, Smock KJ, DeAngelis MM, Clayton FC, Vitale AT, Rodgers G (2012). An inherited disorder with splenomegaly, cytopenias, and vision loss. American journal of medical genetics. Part A, 158A(3), 475-81.
  36. Streiff MB, Holmstrom B, Ashrani A, Bockenstedt PL, Chesney C, Eby C, Fanikos J, Fenninger RB, Fogerty AE, Gao S, Goldhaber SZ, Hendrie P, Kuderer N, Lee A, Lee JT, Lovrincevic M, Millenson MM, Neff AT, Ortel TL, Paschal R, Shattil S, Siddiqi T, Smock KJ, Soff G, Wang TF, Yee GC, Zakarija A, McMillian N, Engh A (2015). Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. Journal of the National Comprehensive Cancer Network, 13(9), 1079-95.
  37. Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, Fanikos J, Fenninger RB, Fogerty AE, Gao S, Goldhaber SZ, Gundabolu K, Hendrie P, Lee AI, Lee JT, Mann J, McMahon B, Millenson MM, Morton C, Ortel TL, Ozair S, Paschal R, Shattil S, Siddiqi T, Smock KJ, Soff G, Wang TF, Williams E, Zakarija A, Hammond L, Dwyer MA, Engh A (2018). NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. Journal of the National Comprehensive Cancer Network, 16(11), 1289-1303.
  38. Wilcox R, Pendleton RC, Smock KJ, Rodgers G (2011). Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice. Hospital practice (1995), 39(3), 23-34.
  39. Smock KJ, Perkins S (2014). Thrombocytopenia: an update. International journal of laboratory hematology, 36(3), 269-78.
  40. Zantek ND, Hsu P, Meijer P, Smock KJ, Plumhoff EA, Refaai MA, Van Cott E (2015). Quality of factor XI activity testing in North American Specialized Coagulation Laboratories. International journal of laboratory hematology, 37 Suppl 1, 99-107.
  41. Sono-Koree N, Crist RA, Heikal NM, Rodgers GM, Smock K (2016). A high-performance liquid chromatography method for the serotonin release assay is equivalent to the radioactive method. International journal of laboratory hematology, 38(1), 72-80.
  42. Pandey S, Post SR, Alapat DV, Smock KJ, Post G (2013). Prolonged prothrombin time correlates with serum immunoglobulin levels in patients with plasma cell dyscrasia. International journal of laboratory hematology, 35, 421-27.
  43. Crist RA, Heikal NM, Rodgers GM, Grenache DG, Smock K (2018). Evaluation of a new commercial method for von Willebrand factor multimeric analysis. International journal of laboratory hematology, 40(5), 586-591.
  44. Smock KJ, Moser K (2019). What have we learned from coagulation laboratory participation in external quality programs?. International journal of laboratory hematology, 41 Suppl 1, 49-55.
  45. Hayward CPM, George TI, Van Cott EM, Smock K (2020). Patient advocacy and its importance to laboratory medicine practice. International journal of laboratory hematology, 42 Suppl 1, 21-22.
  46. Smock K (2021). ADAMTS13 testing update: Focus on laboratory aspects of difficult thrombotic thrombocytopenic purpura diagnoses and effects of new therapies. International journal of laboratory hematology, 43 Suppl 1, 103-108.
  47. Smock KJ, Agarwal AM, Lim MS, Tripp SR, Miles RR, Patel JL, Abromowitch M, Lones MA, Cairo MS, Perkins S (2014). Expression of Notch1 and mTOR Pathway Proteins in Pediatric Lymphoblastic Lymphoma; A Children’s Oncology Group Report. Journal of hematopathology, 7(1), 9-14.
  48. Smock KJ, Schmidt RL, Hadlock G, Stoddard G, Grainger D, Munger M (2014). Assessment of orally-dosed commercial silver nanoparticles on human ex vivo platelet aggregation. Nanotoxicology, 8(3), 328-33.
  49. Smock K (2016). The role of ADAMTS13 testing in the work-up of patients with suspected thrombotic thrombocytopenic purpura. Clinical Laboratory News, 42(4), 10-14.
  50. Pikta M, Vasse M, Smock KJ, Moser KA, van DM, Lejniece S, Szanto T, Bautista H, Nouadje G, Banys (2022). Establishing reference intervals for von Willebrand factor multimers. Journal of medical biochemistry, 41(1), 115-121.
  51. Abou-Ismail MY, Moser KA, Smock KJ, Lim M (2021). Vaccine-induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism. American journal of hematology, 96(9), E346-E349.
  52. Smock KJ, Moser K (2021). Cryptogenic oozers and bruisers. Hematology. American Society of Hematology. Education Program, 2021(1), 85-91.
  53. Moser KA, Smock K (2021). Direct oral anticoagulant (DOAC) interference in hemostasis assays. Hematology. American Society of Hematology. Education Program, 2021(1), 129-133.
  54. Kanack AJ, Singh B, George G, Gundabolu K, Koepsell SA, Abou-Ismail MY, Moser KA, Smock KJ, Green D, Major A, Chan CW, Wool GD, Reding M, Ashrani AA, Bayas A, Grill DE, Padmanabhan (2022). Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies. American journal of hematology, 97(5), 519-526.
  55. Kanack AJ, Bayas A, George G, Abou-Ismail MY, Singh B, Kohlhagen MC, Splinter NP, Christ M, Naumann M, Moser KA, Smock KJ, Grazioli A, Wen R, Wang D, Murray DL, Padmanabhan (2022). Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT. Blood, 140(1), 73-77.
  56. Abou-Ismail MY, Kanack AJ, Splinter NP, Smock KJ, Moser KA, Padmanabhan (2022). Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT. Blood advances, 6(18), 5327-5329.
  57. Smock K (2023). Von Willebrand factor testing ratios in the diagnosis and subtyping of von Willebrand disease. International journal of laboratory hematology, 45 Suppl 2, 23-29.
  58. Smock KJ, Moser K (2023). Automation of a Factor XIII Activity Assay Utilizing a Plasma Blank Measurement. Methods in molecular biology (Clifton, N.J.), 2663, 693-706.
  59. Salazar E, Long TA, Smock KJ, Wool GD, Rollins-Raval M, Chen D, Harris NS, Chan CW, Olson JD, Pham HP, Ritter J, Unold D, VanSandt AM, Goodwin Iv A (2022). Analysis of College of American Pathologists von Willebrand Factor Proficiency Testing Program. Seminars in thrombosis and hemostasis, 48(6), 690-699.
  60. Goodwin AJ, Higgins RA, Moser KA, Smock KJ, Chandler WL, Kottke-Marchant K, Hartman SK, Volod O, Brown AF, Johari VP, Burr S, Polyakov N, Chen (2017). Issues Surrounding Age-Adjusted d-Dimer Cutoffs That Practicing Physicians Need to Know When Evaluating Patients With Suspected Pulmonary Embolism. Annals of internal medicine, 166(5), 361-363.
  61. Jennings I, Meijer P, Arunachalam S, Marlar RA, Olson JD, Zantek ND, Bon C, Dean E, Hollestelle MJ, Meley R, Plumhoff EA, Reilly-Stitt C, Salazar E, Smock KJ, Spannagl M, Walker I (2025). Comparison of Thrombophilia Assay Results for the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee Plasma Standard from Different External Quality Assessment Providers-for the External Quality Assurance in Thrombosis and Haemostasis Group. Seminars in thrombosis and hemostasis, 51(6), 660-666.
  62. Greene DN, Ahmed SB, Daccarett S, Kling JM, Lorey TS, Rytz CL, Smock KJ, Winston-McPherson (2025). A Comprehensive Review of Estradiol, Progesterone, Luteinizing Hormone, and Follicle-Stimulating Hormone in the Context of Laboratory Medicine to Support Women's Health. Clinical chemistry, 71(8), 842-857.
  63. Smock KJ and Zantek N Quality assurance in platelet function testing. Clinics in laboratory medicine,
  64. Kanack AJ, Splinter NP, Mauch EE, Tefera L, Gil MR, Jasra S, Goodwin A, Smock KJ, Ahmad H, Ashrani A, Robinson NL, Casanegra AI, Jones CG, Pechauer SM, Yttre E, Aster RH, Kohlhagen MC, Leger RR, Murray DL, Zhou L, Wang D, Wen R, Chen D, Pruthi RK, Padmanabhan (2025). Pathogenic PF4/Polyvinylsulfonate ELISA-negative Antibodies in HIT. medRxiv,
  65. Saadalla A, Doyle K, Moser K, Smock (2025). Determination of Fibrinogen Ratio Cutoff Limits Using Indirect Reference Interval Methodology. International journal of laboratory hematology, 47(6), 1171-1177.
  66. Kanack A, Mauch E, Roberge G, Splinter N, Gundabolu K, Wool GD, George G, Abou-Ismail MY, Smock KJ, Green DL, Coker J, Kohlhagen MC, Murray DL, Padmanabhan (2025). Platelet Factor 4 Antibody Persistence and Long-term Pathogenicity in Vaccine-induced Immune Thrombotic Thrombocytopenia. medRxiv,
  67. Ji Y, Brunk L, Bove B, Danyal K, Langman LJ, Mot N, Mroz P, Natowicz M, Reddi H, Shirts B, Smock K, Wool GD, Zhang BM, Moyer A (2025). Pharmacogenomic Testing. Archives of pathology & laboratory medicine,
  68. Sanchez Oviol Z, Sorensen ES, Carmona P, Zumberg MS, Smock KJ, Moser K, Chen D, Harris NS, Marin M (2026). A Diagnostic Journey through a Rare Hemostatic Disorder. The journal of applied laboratory medicine,
  69. Salazar E, Smock KJ, Cazzolli T, Dlott JS, Lickteig N, Long TA, Mulvey JJ, Gil MR, Rollins-Raval M, Teruya J, Volod O, Walker CA, Wool GD, Zantek ND, Goodwin Iv A (2026). D-Dimer Reporting and Harmonization: Analysis of College of American Pathologists D-Dimer Proficiency Testing Program. Seminars in thrombosis and hemostasis,
  70. Williamson J, Smock K, Moser K, King R Concurrent acquired hemophilia A and lupus anticoagulant managed with emicizumab and immunosuppression: A case report. Case reports in hematology,

Book Chapter

  1. Smock KJ, Heikal N (2015). Laboratory Assays for ADAMTS-13.
  2. Smock K (2015). Pharmacogenetic Testing for Anticoagulant and Antiplatelet therapies.
  3. Smock KJ, Perkins S (2013). Examination of the Blood and Bone Marrow.
  4. Smock K (2018). Examination of the Blood and Bone Marrow.
  5. Smock KJ, Friedman K (2022). Laboratory Hematology (Chapter 12).
  6. Smock K (2023). Examination of the Blood and Bone Marrow.
  7. Smock KJ, Volod (2023). Viscoelastic Testing and Bleeding Disorders (Chapter 12).
  8. Smock K (2024). Coagulation Laboratory Testing.

Editorial

  1. Van Cott EM, Smock KJ, Lippi (2019). Innovations in Thrombosis and Hemostasis: A Glimpse Toward the Future of Diagnostic Analyzers. Sem Thromb Haemost, 45(3), 225-227.
  2. Smock KJ, Gosselin R (2023). Laboratory Diagnostics for Thrombosis and Hemostasis Testing-Part II. Seminars in thrombosis and hemostasis, 49(6), 569-570.
  3. Pruthi RK, Smock K, Hayward CP (2023). Memorial notice: William L. Nichols, MD. International journal of laboratory hematology, 45(2), 139-140.
  4. Smock KJ, Gosselin R (2022). Laboratory Diagnostics for Thrombosis and Hemostasis Testing-Part I. Seminars in thrombosis and hemostasis, 48(6), 631-633.
  5. Smock KJ, Moffat K (2024). Laboratory Diagnostics for Thrombosis and Hemostasis Testing-Part 3. Seminars in thrombosis and hemostasis, 59(8), 1047-1048.
  6. Smock KJ, Moffat K (2025). Laboratory Diagnostics for Thrombosis and Hemostasis Testing-Part IV. Seminars in thrombosis and hemostasis, 51(6), 627-628.

Letter

  1. Moser KA, Pearson LN, Pelt CE, Olson JD, Goodwin AJ, Isom JA, Harris NS, Pham HP, Smock KJ, Unold D, VanSandt AM, Volod O, Chen (2020). Letter to the Editor on "The 2018 Definition of Periprosthetic Hip and Knee Infection: An Evidence-Based and Validated Criteria". The Journal of arthroplasty, 35(9), 2682-2683.

Abstract

  1. Crist RA, Smock KJ, Rodgers GM, Heikal N (2018). A correlation study of ADAMTS13 neutralizing and non-neutralizing antibodies. American journal of hematology, 93(9), E253-328.
  2. Crist RA, Heikal NM, Rodgers GM, Smock K (2016). Avoiding underestimation of protein S activity in APC resistant specimens. American journal of hematology, 91(9), E363-430, #T19.
  3. Nance D,Campbell RA, Rowley JW, Downie JM, Jorde LB, Kahr WH, Smock KJ, Mereby SA, Manne BK, Tolley ND, Zimmerman GA, Weyrich AS, Rondina M (2016). Combined variants in factor VIII and PTGS-1 amplify hemorrhage severity across three generations of descendants. American journal of hematology, 91(9), E363-430, #4.
  4. Staddon J, Smock K, Schiffman J, Engel M, Fluchel M, Weyrich (2014). Pegasparaginase treatment in pediatric acute lymphoblastic malignancy alters thrombin generation through modulation of the protein C and S system. Pediatric blood & cancer, 61(S1), S1-104.
  5. Sono-Koree N, Crist RA, Heikal NM, Rodgers GM, Smock K (2015). A high-performance liquid chromatography method for the serotonin release assay is equivalent to the radioactive method. International journal of laboratory hematology, 2015(Supp 2), 1-130, #24.
  6. Heikal NM, Crist RA, Rodgers GM, Smock K (2015). The serotonin release assay should be the first-line test for heparin-induced thrombocytopenia in patients with antiphospholipid antibodies. International journal of laboratory hematology, 37(Supp 2), 1-130, #214.
  7. Crist RA, Sono-Koree N, Heikal NM, Rodgers GM, Smock K (2015). Automation of a factor XIII activity assay utilizing a plasma blank improves the quantitation of factor XIII activity. International journal of laboratory hematology, 37(Supp 2), 1-130, #201.
  8. Rudolf J, Smock K, Jackson B, Schmidt (2016). Benchmarking utilization with population prevalence data: A novel use of national census data. Journal of pathology informatics, 7, 33.
  9. Crist RA, Heikal NM, Rodgers GM, Grenache DG, Kunzler TM, Choi MA, Smock K (2017). Evaluation of a New Commercial Method for von Willebrand Factor Multimeric Analysis. 39(S2), 31.
  10. Liederman Z, Van Cott EM, Smock KJ, Meijer P, Selby (2018). Heparin-induced thrombocytopenia: An international assessment of the quality of laboratory testing. 2(S1), 1-368, #PB570.
  11. Crist RA, Rodgers GM, Smock KJ, Moser K (2019). Real world results from an ADAMTS13 reflexive panel performed in a reference laboratory. 41(S2), 1-205.
  12. Pikta M, Vasse M, Lejniece, Smock KJ, Moser KA, Bautista H, Nouadje G, Banys (2020). Establishing reference intervals for von Willebrand factor multimer fractions.
  13. Crist RA, Stephens DA, Rodgers GM, Corean J, Moser KA, Smock KJ. (2020). Performance characteristics of a chromogenic factor VIII method on the STA-R Evolution XP.
  14. Stephens DA, Crist RA, Rodgers GM, Smock KJ, Moser K (2020). Stephens DA, Crist RA, Rodgers GM, Smock KJ, Moser KA. Retrospective analysis of ten years of PT and aPTT validation data in a reference lab. .
  15. Stephens DA, Crist RA, Rodgers GM, Smock KJ, Moser K (2021). A National Reference Laboratory’s Review of Test Ordering Patterns and Positivity Rates During the COVID-19 Pandemic.
  16. Singh B, Kanack A, Bayas A, George G, Abou-Ismail MY, Kohlhagen M, Christ M, Naumann M, Moser K, Smock K, Grazioli A, Murray D, Padmanabhan (2021). Monoclonal and oligoclonal anti-PF4 antibodies mediate VITT. 138(S1), 3220.
  17. Knoebl P, Sanchez-Lucertos A, Scully M, Sathar J, Veyradier A, Mancini I, Fretwell R, Cuker A, Smock K, Meijer P, Binder NB, Peyvandi F, Zheng L, Haberichter S, Vanhooreelbeke K, Kremer-Hovinga J (2023). Knoebl P, Sanchez-Lucertos A, Scully M, Sathar J, Veyradier A, Mancini I, Fretwell R, Cuker A, Smock K, Meijer P, Binder NB, Peyvandi F, Zheng L, Haberichter S, Vanhooreelbeke K, Kremer-Hovinga JA. Towards the standrdisation of ADAMTS-13antibody testing in thrombotic thrombocytopenic purpura (TTP)- results of the IMATAS collaborative study (PB0313). 7(S2), 806 of 1126.
  18. Crist RA, Stephens DA, Rodgers GM, Moser KA, Smock K (2023). Effect of three factor Xa inhibitors on common coagulation assays . 98(S1), E1-E128.
  19. Padmanabhan A, Kanack A, Singh B, George G, Gundabolu K, Koepsell S, Abou-Ismail Y, Moser K, Smock K, Green D, Major A, Chan C, Wool G, Reding M, Ashrani A, Bayas A, Grill (2022). Persistence of Ad26.COV2.S-associated VITT and specific detection of VITT antibodies. 6(S1), e12787.
  20. Moser KA, Lim MY, Smock K (2023). Pathologist-driven reflexive evaluation of prolonged clotting times: A national reference laboratory experience. 98(S1), E1-E128.
  21. Jennings I, Meijer P, Arunachalam S, Olson J, Marlar RA, Zantek N, Bon C, Dean E, Bon C, Dean E, van Essen-Hollestelle MJ, Kutsch M, Meley R, Plumhoff E, Salazar E, Smock K, Spannagl M, Reilly-Stitt C, Unold D, Walker I (2023). Comparison of thrombophilia assay results for the ISTH/SSC Plasma Standard from different EQA providers – data from the EQATH group. 7(S2), 1-1126.
  22. Kanack A, Guillaume R, Mauch E, Splinter N, Wool GD, George G, Abou-Ismail MY, Smock KJ, Green DL, Gundabolu K, Coker J, Kohlhagen M, Murray D, Padmanabhan (2024). Clonal persistence of anti-PF4 antibodies in VITT represents and MGTS-like state. . 144(S1), 1227.
  23. Moser KA, Montgomery S, Smock K (2026). HIT ELISA OD values demonstrate significant variability. 48(Suppl1), 4-96.

Other

  1. Tebo AE, Smock KJ, Branch W (2011). Laboratory diagnostic assays for antiphospholipid syndrome. 51(3),
  2. National Comprehensive Cancer Network (NCCN) Guidelines Panel Members, Cancer-Associated Venous Thromboembolic Disease: Streiff MB, Holmstrom B, Angelini D, Ashrani A, Elshoury A, Fanikos J, Kleber YF, Fogerty AE, Gao S, Goldhaber S, Gundabolu K, Lake L, Leavitt AD, Lee A, Lee JT, Mann J, McMahon B, Morton C, Ortel TL, Paschal R, Schaefer J, Shattil S, Siddiqi T, Smock KJ, Soff G, Sudheendra D, Wang TF, Williams E, Zakarija (2015). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Cancer-Associated Venous Thromboembolic Disease.
  3. McGonnagl (2026). Interviewed for CAP Today, January 2026 issue. Direct oral anticoagulants - new guidance, lab testing (also discussed lab automation, middleware, viscoelastic testing). .